Sequoia Financial Advisors LLC Has $357,000 Stock Holdings in Smith & Nephew SNATS, Inc. $SNN

Sequoia Financial Advisors LLC boosted its stake in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 56.3% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 11,645 shares of the medical equipment provider’s stock after purchasing an additional 4,195 shares during the period. Sequoia Financial Advisors LLC’s holdings in Smith & Nephew SNATS were worth $357,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. Yousif Capital Management LLC bought a new stake in Smith & Nephew SNATS in the second quarter valued at approximately $217,000. Allspring Global Investments Holdings LLC raised its stake in Smith & Nephew SNATS by 4.8% in the second quarter. Allspring Global Investments Holdings LLC now owns 12,462 shares of the medical equipment provider’s stock valued at $381,000 after buying an additional 570 shares during the period. Vanguard Personalized Indexing Management LLC raised its stake in Smith & Nephew SNATS by 6.1% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 34,688 shares of the medical equipment provider’s stock valued at $1,063,000 after buying an additional 1,982 shares during the period. Sivik Global Healthcare LLC raised its stake in Smith & Nephew SNATS by 16.7% in the second quarter. Sivik Global Healthcare LLC now owns 140,000 shares of the medical equipment provider’s stock valued at $4,288,000 after buying an additional 20,000 shares during the period. Finally, Inspire Investing LLC bought a new stake in Smith & Nephew SNATS in the second quarter valued at approximately $223,000. 25.64% of the stock is owned by institutional investors and hedge funds.

Smith & Nephew SNATS Price Performance

Smith & Nephew SNATS stock opened at $36.56 on Wednesday. The stock’s fifty day moving average price is $36.72 and its two-hundred day moving average price is $31.86. Smith & Nephew SNATS, Inc. has a one year low of $23.69 and a one year high of $38.79. The company has a debt-to-equity ratio of 0.60, a current ratio of 3.00 and a quick ratio of 1.40. The firm has a market cap of $15.60 billion, a PE ratio of 16.92, a price-to-earnings-growth ratio of 0.99 and a beta of 0.69.

Smith & Nephew SNATS Cuts Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Friday, November 7th. Shareholders of record on Friday, October 3rd will be paid a dividend of $0.285 per share. This represents a yield of 165.0%. The ex-dividend date is Friday, October 3rd. Smith & Nephew SNATS’s dividend payout ratio (DPR) is 26.39%.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Wall Street Zen lowered Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research note on Friday, October 3rd. Canaccord Genuity Group upped their price objective on Smith & Nephew SNATS from $28.00 to $36.00 and gave the company a “hold” rating in a research note on Monday, August 18th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research note on Wednesday, October 8th. Royal Bank Of Canada reiterated an “outperform” rating on shares of Smith & Nephew SNATS in a research note on Monday. Finally, Sanford C. Bernstein set a $37.50 target price on Smith & Nephew SNATS and gave the stock a “market perform” rating in a research note on Tuesday, October 14th. One research analyst has rated the stock with a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $36.75.

Smith & Nephew SNATS Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.